

# **Durability of Omicron-neutralizing serum activity following mRNA booster immunization in elderly individuals**

Kanika Vanshylla<sup>1,\*</sup>, Pinkus Tober-Lau<sup>2,\*</sup>, Henning Gruell<sup>1,\*</sup>, Friederike Münn<sup>2</sup>, Ralf Eggeling<sup>3</sup>, Nico Pfeifer<sup>3,4,5</sup>, N. Han Le<sup>2</sup>, Irmgard Landgraf<sup>6</sup>, Florian Kurth<sup>2,7,\*</sup>, Leif E. Sander<sup>2,\*</sup>, Florian Klein<sup>1,8,9,\*</sup>

1 Laboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany

2 Department of Infectious Diseases and Respiratory Medicine, Charité-Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany

3 Methods in Medical Informatics, Department of Computer Science, University of Tübingen, Tübingen, Germany

4 Faculty of Medicine, University of Tübingen, Tübingen, Germany

5 German Center for Infection Research, partner site Tübingen, Tübingen, Germany

6 Hausarztpraxis am Agaplesion Bethanien Sophienhaus, Berlin, Germany

7 Department of Tropical Medicine, Bernhard Nocht Institute for Tropical Medicine and Department of Medicine I, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

8 German Center for Infection Research, partner site Bonn-Cologne, Cologne, Germany

9 Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany

\* These authors contributed equally

Correspondence should be addressed to [leif-erik.sander@charite.de](mailto:leif-erik.sander@charite.de) and [florian.klein@uk-koeln.de](mailto:florian.klein@uk-koeln.de)

**NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

38 **Abstract**

39 Elderly individuals are at high risk for severe COVID-19. Due to modest vaccine responses  
40 compared to younger individuals and the time elapsed since prioritized vaccinations, the  
41 emerging immune-evasive Omicron variant of SARS-CoV-2 is a particular concern for the  
42 elderly. Here we longitudinally determined SARS-CoV-2-neutralizing serum activity against  
43 different variants in a cohort of 37 individuals with a median age of 82 years. Participants were  
44 followed for 10 months after an initial two-dose BNT162b2 vaccination and up to 4.5 months  
45 after a BNT162b2 booster. Detectable Omicron-neutralizing activity was nearly absent after  
46 two vaccinations but elicited in 89% of individuals by the booster immunization. Neutralizing  
47 titers against the Wu01, Delta, and Omicron variants showed similar post-boost declines and  
48 81% of individuals maintained detectable activity against Omicron. Our study demonstrates the  
49 mRNA booster effectiveness in inducing Omicron neutralizing activity and provides critical  
50 information on vaccine response durability in the highly vulnerable elderly population.

51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72

73 **Text**

74 Advanced age is a critical risk factor for morbidity and mortality associated with  
75 SARS-CoV-2 infection. Elderly individuals have therefore been prioritized for COVID-19  
76 vaccination. Moreover, lower vaccine immunogenicity in older compared to younger  
77 individuals and more pronounced waning of humoral immunity have prompted early booster  
78 campaigns in the elderly.<sup>1</sup> The recently emerged Omicron variant (BA.1) of SARS-CoV-2 is  
79 associated with a marked reduction in sensitivity to vaccine-induced serum neutralizing activity  
80 and is therefore of particular concern for the elderly.<sup>2</sup> However, while booster immunizations  
81 can elicit Omicron-neutralizing activity,<sup>3</sup> their immediate and long-term effects in highly aged  
82 individuals are not yet determined. This limits informed guidance of vaccination strategies in  
83 this vulnerable population.

84

85 Here, we longitudinally determined SARS-CoV-2-neutralizing serum activity in a prospective  
86 cohort of 37 individuals with a median age of 82 years (range 76-96 years; appendix p 2).<sup>4</sup>  
87 Participants were followed for 10 months after an initial two-dose BNT162b2 vaccination and  
88 up to 4·5 months after a single booster dose of BNT162b2. 50% geometric mean inhibitory  
89 serum dilutions (GeoMean ID<sub>50</sub>s) against the Wu01 vaccine strain as well as the Delta and  
90 Omicron variants were determined using a pseudovirus assay (appendix p 4).

91

92 Following completion of the initial two-dose regimen, sera were collected at 1 (median 26 days,  
93 interquartile range [IQR] 25-27; *V1*) and 5 months (median 153 days; IQR 151-154; *V2*). Two  
94 doses of BNT162b2 induced detectable neutralizing activity against Wu01 and Delta in the  
95 majority of individuals (95% and 84%, respectively), while activity against Omicron was not  
96 or only minimally detectable (figure). Over the subsequent 4 months, neutralizing serum titers  
97 against Wu01 and Delta declined by 6- (GeoMean ID<sub>50</sub> of 265 to 42) and 7-fold (GeoMean ID<sub>50</sub>  
98 of 89 to 13), respectively.

99

100 All individuals received a third dose of BNT162b2 at 7 months (median 209 days, IQR 189-  
101 228) and early post-boost serum samples were obtained 1 month later (median 23 days, IQR  
102 21-29, *V3*). Booster immunization resulted in a more than 50-fold increase in neutralizing titers  
103 against Wu01 and Delta (GeoMean ID<sub>50</sub>s of 2912 and 750, respectively). Importantly, the  
104 booster dose of BNT162b2 elicited a robust neutralizing activity against the Omicron variant  
105 (GeoMean ID<sub>50</sub> of 256) in 33 out of the 37 elderly participants (89%; figure). Of the four non-

106 responders, one participant suffered from an active hematological malignancy and did not  
107 develop neutralizing reactivity against all of the tested variants at any time point.

108

109 To determine the durability of SARS-CoV-2 serum neutralizing activity after booster  
110 immunization in elderly individuals, we obtained follow-up samples 3-5 months (median 106  
111 days, IQR 86-125) after the third vaccination. Neutralizing titers declined by 2·7-, 2·3-, and  
112 3·0-fold to GeoMean ID<sub>50</sub>s of 1077, 345, and 85 against the Wu01, Delta, and Omicron  
113 variants, respectively. However, most participants maintained detectable neutralization against  
114 Wu01 (97%), Delta (95%), and Omicron (81% total; 91% of individuals with detectable activity  
115 at the early post-boost visit V3). To evaluate the rate of the decline in serum neutralizing  
116 activity, we used linear mixed-effects models to separately analyze the periods before and after  
117 the booster immunization (appendix p 3). Neutralizing activity against the different variants  
118 showed similar changes after the booster immunization with estimated half-lives of  
119 approximately 52 (95% confidence interval [CI], 46-59), 64 (95% CI 52-83), and 41 (95% CI  
120 34-52) days against Wu01, Delta, and Omicron, respectively (appendix p 3).

121

122 In the absence of Omicron-specific vaccines, booster immunizations are critical to restore  
123 waning vaccine effectiveness and to reduce the risk of severe outcomes.<sup>5</sup> Our study  
124 demonstrates that booster immunizations can effectively elicit Omicron-neutralizing activity in  
125 the majority of aged individuals (median age 82 years). While our analysis was limited to two  
126 sampling time points with different observational periods before and after the boost, our results  
127 suggest that neutralizing activity against different variants is maintained with similar decay  
128 rates. Although neutralizing serum activity does not equal protection from infection, the results  
129 suggest that previous experience regarding waning humoral immunity can serve as guidance  
130 for vaccination strategies against Omicron in the elderly population.

131

### 132 **Acknowledgements**

133 We thank all study participants for their dedication to our research. We thank the members of  
134 the COVIMMUNIZE/COVIM Study Group for sample acquisition and processing (Y.  
135 Ahlgrimm, B. Al-Rim, K. Behn, N. Bethke, H. Bias, D. Briesemeister, C. Conrad, V.M.  
136 Corman, C. Dang-Heine, S. Dieckmann, D. Frey, J.-A. Gabelich, J. Gerdes, U. Gläser, L.  
137 Hasler, E.T. Helbig, A. Hetey, D. Hillus, W.G. Hirst, A. Horn, C. Hülso, S. Jentzsch, C. von  
138 Kalle, L. Kegel, A. Krannich, W. Koch, P. Kopankiewicz, P. Kroneberg, L.J. Lippert, M. Lisy,  
139 C. Lüttke, P. de Macedo Gomes, B. Maeß, J. Michel, A. Nitsche, A.-M. Ollech, C. Peiser, A.

140 Pioch, C. Pley, K. Pohl, A. Richter, M. Rönnefarth, L. Ruby, C. Rubisch, A. Sanchez Rezza, I.  
141 Schellenberger, V. Schenkel, J. Schlesinger, S. Schmidt, G. Schwanitz, T. Schwarz, S.  
142 Senaydin, J. Seybold, A.-S. Sinnigen, A. Solarek, A. Stege, S. Steinbrecher, P. Stubbemann, C.  
143 Thibeault, D. Treue, and S. Zvorc). This work was supported through grants from COVIM:  
144 NaFoUniMedCovid19 (FKZ: 01KX2021) to LES and FKI, the German Center for Infection  
145 Research (DZIF) to FKI, the Federal Institute for Drugs and Medical Devices (V-2021.3 /  
146 1503\_68403 / 2021–2022) to FKU and LES, the Deutsche Forschungsgemeinschaft (DFG)  
147 SFB-TR84 to LES and CRC1310 to FKI, and a donation from Zalando SE to Charité –  
148 Universitätsmedizin Berlin. The funders had no role in study design, data collection and  
149 analysis, manuscript preparation, or the decision to submit for publication.

150

### 151 **Declaration of interests**

152 KV, HG, and FKI are listed as inventors on patent application(s) regarding SARS-CoV-2-  
153 neutralizing antibodies filed by the University of Cologne. All other authors declare no  
154 competing interests.

155

### 156 **Figure legend**

157

158 **Figure. Longitudinal assessment of SARS-CoV-2-neutralizing serum activity in elderly**  
159 **individuals.** Serum ID<sub>50</sub>s against the Wu01, Delta, and Omicron variants, determined using  
160 pseudovirus neutralization assays. Lines in (A) connect visits for each individual and gray areas  
161 indicate booster administration period. Lines in (B) indicate geometric mean ID<sub>50</sub>s with 95%  
162 confidence intervals for each study visit. Numbers show geometric mean ID<sub>50</sub>s and percentage  
163 of individuals with detectable neutralizing activity (ID<sub>50</sub>>LLOQ) in parentheses. Dotted lines  
164 indicate LLOQ. V1-V4 indicate consecutive study visits. ID<sub>50</sub>, 50% inhibitory dilution; LLOQ,  
165 lower limit of quantification.


166

### 167 **References**

- 168 1. Levin EG, Lustig Y, Cohen C, et al. Waning Immune Humoral Response to BNT162b2  
169 Covid-19 Vaccine over 6 Months. *N Engl J Med.* 2021; **385**(24): e84.
- 170 2. Cele S, Jackson L, Houry DS, et al. Omicron extensively but incompletely escapes  
171 Pfizer BNT162b2 neutralization. *Nature.* 2021.
- 172 3. Schmidt F, Muecksch F, Weisblum Y, et al. Plasma Neutralization of the SARS-CoV-  
173 2 Omicron Variant. *N Engl J Med.* 2021.
- 174 4. Tober-Lau P, Schwarz T, Vanshylla K, et al. Long-term immunogenicity of BNT162b2  
175 vaccination in older people and younger health-care workers. *Lancet Resp Med.* 2021;  
176 **9**(11): e104-e5.

- 177 5. Barda N, Dagan N, Cohen C, et al. Effectiveness of a third dose of the BNT162b2  
178 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational  
179 study. *Lancet*. 2021; **398**(10316): 2093-100.  
180  
181

## Figure



**Figure. Longitudinal assessment of SARS-CoV-2-neutralizing serum activity in elderly individuals.**

Serum ID<sub>50</sub>s against the Wu01, Delta, and Omicron variants, determined using pseudovirus neutralization assays. Lines in (A) connect visits for each individual and grey areas indicate booster administration period. Lines in (B) indicate geometric mean ID<sub>50</sub>s with 95% confidence intervals for each study visit. Numbers show geometric mean ID<sub>50</sub>s and percentage of individuals with detectable neutralizing activity (ID<sub>50</sub>>LLOQ) in parentheses. Dotted lines indicate LLOQ. V1-V4 indicate consecutive study visits. ID<sub>50</sub>, 50% inhibitory dilution; LLOQ, lower limit of quantification.